Journal
ONCOGENE
Volume 38, Issue 23, Pages 4429-4451Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/s41388-019-0741-6
Keywords
-
Funding
- Instituto de Salud Carlos III [PI16/00772, CPII16/00042]
- European Regional Development Fund (ERDF)
- Norwegian Cancer Society [709125]
- South-Eastern Norway Regional Health Authority [2016013]
- Kristian Gerhard Jebsen Foundation
- Ministerio de Economia y Competitividad, Spain
- Consejeria de Educacion, Junta de Castilla y Leon, Spain [FEDER BFU2015-70040-R]
- FEDER [SA026U16]
- Fundacion Ramon Areces
- Spanish Foundation for Research on Bone and Mineral Metabolism (FEIOMM)
- FECYT-Ministerio de Economia y Competitividad [PRECIPITA-2015-000139]
- Xunta de Galicia [IN607B 2017/21]
- Instituto de Salud Carlos III (ISCIII, Spain) [PI16/00035]
- European Regional Development Fund, 'A way of making Europe' from the European Union
- Worldwide Cancer research grant [08-0159]
- Medical Research Council
- Ligue contre le Cancer (Comites de la Charente-Maritime et de la Vienne)
- MRC [MC_UU_12014/3] Funding Source: UKRI
Ask authors/readers for more resources
Gap junctions comprise arrays of intercellular channels formed by connexin proteins and provide for the direct communication between adjacent cells. This type of intercellular communication permits the coordination of cellular activities and plays key roles in the control of cell growth and differentiation and in the maintenance of tissue homoeostasis. After more than 50 years, deciphering the links among connexins, gap junctions and cancer, researchers are now beginning to translate this knowledge to the clinic. The emergence of new strategies for connexin targeting, combined with an improved understanding of the molecular bases underlying the dysregulation of connexins during cancer development, offers novel opportunities for clinical applications. However, different connexin isoforms have diverse channel-dependent and -independent functions that are tissue and stage specific. This can elicit both pro- and anti-tumorigenic effects that engender significant challenges in the path towards personalised medicine. Here, we review the current understanding of the role of connexins and gap junctions in cancer, with particular focus on the recent progress made in determining their prognostic and therapeutic potential.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available